FDA Advisor Feels Children in Late Teens Should Not Be Included in Pfizer’s Covid-19 Vaccination Drive

 

 

Member of the advisory panel at Food and Drug Administration, Dr. Archana Chatterjee announced her reasons for voting against the authorization of Pfizer’s Covid-19 vaccine for emergency use. She says that she does not believe that children of 16 and 17 years should be included in the vaccination drive as the vaccine has been cleared for use in adults of 18 years and above.

On Friday, Chatterjee, a pediatric infectious disease specialist and dean of the Chicago Medical School, told CNBC that her opposition was based on her belief that the currently 16- and- 17-year-old should be exempted from the emergency use drive.

In a “Squawk Box” interview, Chatterjee said she would have cast a positive vote if the question had been different. “I want to be very clear that I am fully supportive of the emergency use authorization for the use of this vaccine from Pfizer and BioNTech for adults 18 years and older,” said Chatterjee.

The FDA committee has recommended emergency authorization for people of 16 and above.

Reports say that three other members of the FDA advisory panel also voted against recommending Pfizer’s COVID-19 vaccine for emergency use. It is said that one member refrained from casting the vote, but the remaining 17 were in favor of a recommendation.

The vaccine developed by from Pfizer and BioNTech would be the first to obtain regulatory clearance in the United States. The vaccine has been approved by health officials in Canada and the United Kingdom.

Chatterjee noted that the vaccine has shown “really good safety profile overall” as it has proven   to be 95% effective in the clinical trials. She added, “I think that we were pleasantly surprised to see that this vaccine has such good efficacy in tens of thousands of participants that were included in the trial.” She commended Pfizer and BioNTech for their efforts and good intentions behind including people under 18 in the trials.

Chatterjee feels that there needs to be additional data and definitive results before the under-18 recommendation by the companies.

Director of the Precision Vaccines Program at Boston Children’s Hospital, Dr. Ofer Levy, had voted in favor of recommending the vaccine. He told CNBC a “rigorous” safety review process took place, including for 16- and 17-year-olds.

“There was no particularly different safety signal for them as the older individuals, so the majority of the committee members felt comfortable voting ‘yes,’” Levy said Friday on “Worldwide Exchange.”

“Yesterday was a milestone but there is a long road ahead” in the effort to end the coronavirus pandemic, Levy added.

As the doses of the vaccine are likely to be limited in the early days, concerns have been raised regarding its administration to the younger individuals, says Dr. Scott Gottlieb, a Pfizer board member and former FDA chief. “This vaccine isn’t going to be eligible for 16- and-17-year-olds for quite some time … and probably until it gets fully licensed at some point, hopefully if everything goes well, in the spring and summertime,” Gottlieb said on “Squawk Box”.

Source: CNBC

Phoot- Image by Vijay Hu from Pixabay


Follow us on Google news for more updates and News










PLEASE READ THE IMPORTANT DISCLOSURES BELOW.

This content is being provided to you for informational purposes only. The content has been prepared by third parties not affiliated with CWEB Inc, a business. This content and any information contained therein, does not constitute a recommendation by CWEB to buy, sell or hold any security, financial product or instrument referenced in the content. This information neither is, nor should be construed as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. CWEB Inc. does not offer or provide any opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make, and such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.

Unless stated otherwise, the web content provided by the CWEB family of companies is for educational purposes only. The information and tools provided neither are, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. or its affiliates. Unless stated otherwise, no information presented constitutes a recommendation by CWEB Inc. or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy.

Full Disclaimer

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.